Loading
Pro DEX Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Philp Katrina Marie Kramer, was filed 12 May 2022.
Pro DEX Inc: what insiders have been doing
Pro DEX Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 22 October 2026, 36 filings were filed, from 10 insiders.
Only sales appear on the open market, 14 sales in all totalling €1.2M, filed by 3 insiders. The largest single trade was a sale of €244k by Van Kirk Richard Lee Jr, published on 10 September 2026, equal to 0.15% of the market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 36 filings, this issuer sits above that mark. Looking back to 2016, when coverage begins, insiders filed 14 purchases and 184 sales. For the fiscal year to 30 June 2026, the annual 10-K puts revenue at 77.5 m USD and net income at 13.7 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
305
Thresholds
n/a
Buy Volume
€498,615
14 ops. · all time
Sell Volume
€12M
184 ops. · all time
Who traded when
BuySaleCabillot Raymond E29 sales
Richard Lee Van Kirk Jr.11 sales
Alisha Charlton3 sales
Swenson Nicholas John2 sales
Angelita Rebamontan Domingo1 sale
Since the insiders bought
- +4.5%Entry US$15.12 · Close at T+365 US$15.80
- -15.8%Entry US$20.50 · Close at T+365 US$17.26
- +25.6%Entry US$13.73 · Close at T+365 US$17.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 4,860 of 26,246 companies
67.9
score / 100
Value62
Quality74
FCF yld3.5%
Earn yld7.0%
EV/EBITDA10.6x
ROE32%
Gross mgn31%
Net mgn18%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$60.56
Analyst consensus
1 analysts1.00/5
US$74.00Target US$74.00(+22%)US$74.00
Income statement
RevenueUS$77.5M
Gross profitUS$24.3M31% margin
EBITDAUS$20.2M26% margin
Net incomeUS$13.7M17.6% margin
Valuation
PER (trailing)14.7x
PER (forward)18.0x
P/Book4.1x
Beta0.04
Balance sheet & cash
Market capUS$195.8M
Total debtUS$18.9M
Free Cash FlowUS$6.8M
Debt / Equity40%
Profitability & ownership
ROE32.4%
ROA12.0%
% insiders36.0%
% institutions31.9%
Last declaration on 14 September 2026
Declarations305 total
290 shares@ US$58.940.0089% mcap0.5% of flowCommon StockSEC:0001079973-26-001259:0
475 shares@ US$59.620.015% mcap0.8% of flowCommon StockSEC:0001079973-26-001259:1
1,500 shares@ US$61.050.047% mcap11.6% of flowCommon StockSEC:0001079973-26-001242:0
800 shares@ US$61.760.026% mcap6.3% of flowCommon StockSEC:0001079973-26-001242:1
2,160 shares@ US$58.920.066% mcap3.4% of flowCommon StockSEC:0001079973-26-001244:0
2,691 shares@ US$59.840.083% mcap4.3% of flowCommon StockSEC:0001079973-26-001244:1
4,274 shares@ US$60.720.13% mcap6.9% of flowCommon StockSEC:0001079973-26-001244:2
1,157 shares@ US$61.880.037% mcap1.9% of flowCommon StockSEC:0001079973-26-001244:3
935 shares@ US$62.930.030% mcap1.6% of flowCommon StockSEC:0001079973-26-001244:4
2,144 shares@ US$63.850.071% mcap3.6% of flowCommon StockSEC:0001079973-26-001244:5
300 shares@ US$64.700.010% mcap0.5% of flowCommon StockSEC:0001079973-26-001244:6
806 shares@ US$58.6590.024% mcap1.3% of flowCommon StockSEC:0001079973-26-001244:7
4,768 shares@ US$59.450.15% mcap7.5% of flowCommon StockSEC:0001079973-26-001244:8
20,000 shares@ US$64.700.67% mcap34.2% of flowCOMMONSEC144:0001949846-26-000573
2,300 shares@ US$73.410.085% mcap100.0% of flowCommon StockSEC144:0001079973-26-001233
19 shares@ US$33.250.0003% mcap0.2% of flowCommon StockSEC:0001079973-26-000970:0
998 shares@ US$47.2412.1% of flowCommon StockSEC:0001553350-26-000103:0
10,800 shares0Common StockSEC:0001079973-26-000910:0
3,897 shares@ US$62.740.10% mcap53.4% of flowCommon StockSEC:0001079973-26-000910:1
6,800 shares0Common StockSEC:0001079973-26-000909:0
14,800 shares0Common StockSEC:0001079973-26-000908:0
2,488 shares@ US$62.740.067% mcap40.3% of flowCommon StockSEC:0001079973-26-000909:1
5,279 shares@ US$62.740.14% mcap11.6% of flowCommon StockSEC:0001079973-26-000908:1
18 shares@ US$34.360.2% of flowCommon StockSEC:0001079973-26-000105:0
2,200 shares@ US$32.7021.0% of flowCommon StockSEC:0001553350-25-000136:1
25 of 305 declarations
About Pro DEX Inc
Pro-Dex Inc. (ticker PDEX) is a niche U.S. medical-device and precision manufacturing company listed on the Nasdaq Capital Market, part of the NASDAQ market in the United States. For French-speaking investors, the company is best viewed as a specialized industrial healthcare supplier rather than a traditional pharmaceutical name. Pro-Dex says it has been in business for more than 40 years, with its corporate headquarters in Irvine, California. Over time, the business has evolved from a broader industrial footprint into a more focused platform centered on product development and contract manufacturing.
Today, Pro-Dex’s core business is the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers. These products are used primarily in the orthopedic, thoracic, and maxillofacial markets. The company also highlights proprietary torque-limiting software and sealing solutions, which support product differentiation and help create technical switching costs for customers. In addition to manufacturing, Pro-Dex offers engineering, quality, regulatory, and consulting services, making it a value-added outsourcing partner for OEM customers in the medical technology ecosystem.
Read moreShow less
From a competitive standpoint, Pro-Dex is not a large diversified med-tech group. Its value proposition is based on specialization, engineering depth, manufacturing responsiveness, and the ability to work closely with major medical and dental product companies. The company states that it has collaborated with some of the world’s largest providers of medical and dental products, which suggests a client base that values reliability, technical customization, and regulatory discipline. Because of its size, revenue concentration is likely to remain an important analytical feature, with a limited number of customers accounting for a meaningful portion of sales.
Geographically, Pro-Dex remains predominantly U.S.-anchored. The company’s headquarters are in Irvine, California, and it describes its outsourcing services as being provided nationwide and beyond. For investors in France, Belgium, or Switzerland, that means the name should be analyzed through the lens of a U.S. industrial healthcare supplier exposed to medical-device purchasing cycles, product launch timing, and the operational demands of regulated manufacturing.
Recent developments have been material. In its fiscal year ended June 30, 2025, Pro-Dex reported strong top-line growth, driven mainly by its largest customer and sales of a next-generation handpiece. More importantly, in December 2025 the company announced a contract amendment extending its largest customer relationship by an additional three years, through December 31, 2028, with minimum purchase volumes for calendar 2026 and 2027. That extension improves medium-term revenue visibility and underscores the strategic importance of this client relationship. As with many small-cap NASDAQ names, investors also watch SEC insider Form 4 filings for additional sentiment signals from management and directors.
